Stratos Wealth Partners LTD. grew its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,279 shares of the company’s stock after purchasing an additional 1,280 shares during the quarter. Johnson & Johnson comprises about 0.6% of Stratos Wealth Partners LTD.’s holdings, making the stock its 26th biggest holding. Stratos Wealth Partners LTD.’s holdings in Johnson & Johnson were worth $22,891,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $4,370,566,000. Sanders Capital LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $1,126,076,000. Morgan Stanley increased its stake in shares of Johnson & Johnson by 7.3% in the 4th quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock worth $3,794,594,000 after acquiring an additional 1,638,263 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Johnson & Johnson by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock worth $5,029,590,000 after acquiring an additional 1,628,229 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Johnson & Johnson by 574.1% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,557,719 shares of the company’s stock worth $245,154,000 after acquiring an additional 1,326,651 shares in the last quarter. Institutional investors and hedge funds own 67.25% of the company’s stock.

NYSE JNJ opened at $165.21 on Tuesday. The company’s 50-day moving average price is $162.67 and its 200-day moving average price is $156.40. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The stock has a market cap of $434.95 billion, a PE ratio of 25.98, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 12 month low of $133.65 and a 12 month high of $173.65.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Monday, April 19th. The company reported $2.59 EPS for the quarter, topping the Zacks’ consensus estimate of $2.34 by $0.25. The firm had revenue of $22.30 billion for the quarter, compared to analysts’ expectations of $22 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.30 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th will be issued a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a yield of 2.57%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.01. The ex-dividend date of this dividend is Monday, May 24th. Johnson & Johnson’s dividend payout ratio is presently 46.54%.

A number of analysts have weighed in on the stock. Cantor Fitzgerald raised their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, January 26th. SVB Leerink raised their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Cowen raised their price objective on shares of Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $168.00 to $193.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a research note on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $182.45.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Cash Asset Ratio

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.